US Patent

US12521396 — Pharmaceutical compositions comprising a MENIN inhibitor

Formulation · Assigned to Kura Oncology Inc · Expires 2044-07-16 · 18y remaining

Vulnerability score 38/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects crystalline forms of a specific compound, methods of making those forms, and pharmaceutical compositions containing them.

USPTO Abstract

Described herein are crystalline forms of (S)-4-methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile or solvate thereof, methods of making such forms, and pharmaceutical composition comprising such forms.

Drugs covered by this patent

Patent Metadata

Patent number
US12521396
Jurisdiction
US
Classification
Formulation
Expires
2044-07-16
Drug substance claim
No
Drug product claim
Yes
Assignee
Kura Oncology Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.